Histide

Founded in 2014 and headquartered in Switzerland, Histide AG is dedicated to biotechnological advancements.Histide™ specializes in the development of innovative non-mutagenic extracellular therapeutic agents known as Cell Recoding Molecules™ (CRM™). These advanced therapeutic solutions leverage the mechanisms of cell microenvironmental sensing and signal transduction to enhance the cell's natural ability to redirect its fate, facilitating a process referred to as Recoding Therapeutics™. This groundbreaking approach enables precise control over cellular behavior without the need for introducing foreign entities into cells, thus minimizing potential harm. Histide's CRM™ technology is designed to target various diseases, including cancer, metabolic disorders, and rare diseases, with applications spanning pharmaceuticals, medical devices, and cosmetics.Histide's revenue generation strategy is primarily centered around forming strategic partnerships and collaborations with pharmaceutical companies and research entities. The company engages in direct-to-business transactions, where clients can procure its proprietary CRM™ technologies for integration into their therapeutic developments. These transactions are structured around licensing agreements and research collaborations, wherein clients benefit from access to Histide's extensive intellectual property portfolio and technological advancements. The revenue model includes milestone payments tied to research breakthroughs and clinical progress, along with potential royalties based on the commercial success of therapies developed using Histide's innovative platform. Specific geographic regions targeted for expansion include North America and Asia, with plans to establish partnerships by the end of 2024.

1. Series A

   Nov 10, 2014

   Amount

   $4.7M

   Investors

   Locked